Work

Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR)

Year: 2017

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(17)30678-0

Authors: M. Schmidinger, R.J. Motzer, T. Powles, B. Escudier, N.M. Tannir, P.N. Mainwaring, B.I. Rini, H.J. Hammers, F. Donscov, B. Roth, K. Peltola, J.L. Lee, D.Y.C. Heng, D.T. Aftab, C. Hessel, C. Scheffold, G. Schwab, S. Pal, T.E. Hutson, T.K. Choueiri

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2587195693

FWCI:

Cites:

Cited by: 1

Related to: 10